Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | FGF1 | P05230 | 1/20 | 0.35 |
| ▸ | FGF2 | P09038 | 1/20 | 0.35 |
| ▸ | VEGFA | P15692 | 1/20 | 0.35 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.35 |
| ▸ | CD209 | Q9NNX6 | 1/20 | 0.33 |
| ▸ | PYGB | P11216 | 5/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29068760 | 0.81 | ADORA1 (0.41) | ADORA1 | |
| SCHEMBL94835 | 0.73 | PYGB (0.44) | FGF1FGF2VEGFAHPSEPYGB | |
| SCHEMBL2510604 | 0.72 | ADORA1 (0.44) | ADORA1FGF1FGF2VEGFAHPSE | |
| SCHEMBL8329378 | 0.72 | ADORA1 (0.44) | ADORA1FGF1FGF2VEGFAHPSE | |
| SCHEMBL574712 | 0.71 | ADORA1 (0.39) | ADORA1 | |
| SCHEMBL5369246 | 0.68 | P2RY14 (0.39) | ADORA1 | |
| SCHEMBL27755867 | 0.68 | ADORA1 (0.36) | ADORA1 | |
| SCHEMBL860142 | 0.68 | ADORA1 (0.37) | ADORA1FGF1FGF2VEGFAHPSE | |
| SCHEMBL27777686 | 0.67 | ADORA1 (0.37) | ADORA1 | |
| SCHEMBL430834 | 0.66 | ADORA1 (0.44) | ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111918960-A | Methods and compositions for preventing microbial infections | 比奥普来克斯有限公司 | 2020-11-10 | — | — | CN | claimed |
| CN-111918960-A | Methods and compositions for preventing microbial infections | 比奥普来克斯有限公司 | 2020-11-10 | — | — | CN | disclosed |